IQVIA provides contract research, clinical-trial execution, healthcare data, and technology services to pharmaceutical and biotechnology companies. It supports drug development through trial design, patient recruitment, monitoring, regulatory and commercial analytics, and real-world evidence. Revenue comes from multi-year outsourced research contracts, technology tools, and data-related services.
IQVIA Holdings Inc. (IQV) has a MarketKingdoms composite score of 68.8 (B), an B-range rating. It ranks 424th of 1,866 covered companies, 17th of 78 in Healthcare (sector average 64.5) and 5th of 13 in Diagnostics & Research. Scores as of 2026-10-25.
Its strongest lenses are KPI momentum at 93 (Healthcare average 78) and Industry opportunity at 90 (Healthcare average 81). Its weakest lenses are Quality (profitability) at 38 (sector average 50) and Price (valuation) at 51 (sector average 50).
| Lens | Type | IQV | Healthcare average | Diagnostics & Research average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 90 | 81 | 90 | 95th |
| Stock selection | Research signal | 86 | 79 | 83 | 91st |
| KPI momentum | Research signal | 93 | 78 | 85 | 94th |
| Catalyst watch | Research signal | 72 | 74 | 77 | 24th |
| Price (valuation) | Fundamental lens | 51 | 50 | 32 | 51st |
| Expansion (growth) | Fundamental lens | 52 | 50 | 52 | 67th |
| Quality (profitability) | Fundamental lens | 38 | 50 | 42 | 33rd |
| Trend (momentum) | Fundamental lens | 79 | 50 | 69 | 91st |
The most recent call analysed was held on 2026-07-28 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -16.5%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 0.56, sector beta 0.10, industry beta 0.91; the factor model explains 60% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Illumina Inc. (ILMN) | 71.0 | B+ | +22.1% |
| Quest Diagnostics Incorporated (DGX) | 69.4 | B | -4.1% |
| Agilent Technologies Inc. (A) | 69.2 | B | -3.1% |
| Revvity Inc. (RVTY) | 69.2 | B | +8.2% |
| Labcorp Holdings Inc. (LH) | 68.8 | B | -13.5% |
| Natera Inc. (NTRA) | 68.5 | B | -22.9% |
| Charles River Laboratories International Inc. (CRL) | 68.0 | B | -15.8% |
| Waters Corp. (WAT) | 67.9 | B | -6.2% |
IQVIA Holdings Inc. financial statements · Healthcare sector ranking · Diagnostics & Research industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.